INCYTE CORP (INCY) Stock Fundamental Analysis
USA - NASDAQ:INCY - US45337C1027 - Common Stock
93.48 USD
+0.89 (+0.96%)
94.5 USD
+1.02 (+1.09%)
Taking everything into account, INCY scores 6 out of 10 in our fundamental rating. INCY was compared to 534 industry peers in the Biotechnology industry. INCY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. INCY is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make INCY suitable for value and quality investing!
1. Profitability
1.1 Basic Checks
In the past year INCY was profitable.
In the past year INCY had a positive cash flow from operations.
INCY had positive earnings in 4 of the past 5 years.
Of the past 5 years INCY 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 14.96%, INCY belongs to the top of the industry, outperforming 95.32% of the companies in the same industry.
INCY's Return On Equity of 20.88% is amongst the best of the industry. INCY outperforms 95.51% of its industry peers.
INCY has a better Return On Invested Capital (17.30%) than 96.82% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for INCY is significantly below the industry average of 15.50%.
The 3 year average ROIC (7.24%) for INCY is below the current ROIC(17.30%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.96% | ||
| ROE | 20.88% | ||
| ROIC | 17.3% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
1.3 Margins
INCY has a better Profit Margin (18.99%) than 94.19% of its industry peers.
In the last couple of years the Profit Margin of INCY has declined.
INCY's Operating Margin of 21.69% is amongst the best of the industry. INCY outperforms 95.32% of its industry peers.
In the last couple of years the Operating Margin of INCY has declined.
INCY has a better Gross Margin (93.41%) than 93.45% of its industry peers.
INCY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.69% | ||
| PM (TTM) | 18.99% | ||
| GM | 93.41% |
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), INCY is creating value.
Compared to 1 year ago, INCY has less shares outstanding
The number of shares outstanding for INCY has been reduced compared to 5 years ago.
Compared to 1 year ago, INCY has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 8.29 indicates that INCY is not in any danger for bankruptcy at the moment.
INCY has a Altman-Z score of 8.29. This is amongst the best in the industry. INCY outperforms 80.52% of its industry peers.
INCY has a debt to FCF ratio of 0.04. This is a very positive value and a sign of high solvency as it would only need 0.04 years to pay back of all of its debts.
INCY's Debt to FCF ratio of 0.04 is amongst the best of the industry. INCY outperforms 96.82% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that INCY is not too dependend on debt financing.
INCY has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: INCY outperforms 44.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.04 | ||
| Altman-Z | 8.29 |
ROIC/WACC1.98
WACC8.74%
2.3 Liquidity
A Current Ratio of 2.85 indicates that INCY has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.85, INCY is doing worse than 65.92% of the companies in the same industry.
INCY has a Quick Ratio of 2.78. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of INCY (2.78) is worse than 64.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.85 | ||
| Quick Ratio | 2.78 |
3. Growth
3.1 Past
INCY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 575.79%, which is quite impressive.
The earnings per share for INCY have been decreasing by -14.21% on average. This is quite bad
The Revenue has grown by 14.76% in the past year. This is quite good.
The Revenue has been growing by 14.46% on average over the past years. This is quite good.
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
Revenue 1Y (TTM)14.76%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
3.2 Future
INCY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.17% yearly.
Based on estimates for the next years, INCY will show a decrease in Revenue. The Revenue will decrease by -0.47% on average per year.
EPS Next Y378.66%
EPS Next 2Y136.69%
EPS Next 3Y88.47%
EPS Next 5Y27.17%
Revenue Next Year15.16%
Revenue Next 2Y13.02%
Revenue Next 3Y11.75%
Revenue Next 5Y-0.47%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 14.56 indicates a correct valuation of INCY.
96.63% of the companies in the same industry are more expensive than INCY, based on the Price/Earnings ratio.
INCY is valuated rather cheaply when we compare the Price/Earnings ratio to 26.10, which is the current average of the S&P500 Index.
INCY is valuated correctly with a Price/Forward Earnings ratio of 12.64.
INCY's Price/Forward Earnings ratio is rather cheap when compared to the industry. INCY is cheaper than 96.63% of the companies in the same industry.
INCY's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.52.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.56 | ||
| Fwd PE | 12.64 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of INCY indicates a rather cheap valuation: INCY is cheaper than 94.76% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, INCY is valued cheaply inside the industry as 95.51% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.05 | ||
| EV/EBITDA | 13.6 |
4.3 Compensation for Growth
INCY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
INCY has a very decent profitability rating, which may justify a higher PE ratio.
INCY's earnings are expected to grow with 88.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y136.69%
EPS Next 3Y88.47%
5. Dividend
5.1 Amount
INCY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
93.48
+0.89 (+0.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners103.23%
Inst Owner Change0.88%
Ins Owners1.85%
Ins Owner Change0.55%
Market Cap18.25B
Revenue(TTM)4.24B
Net Income(TTM)870.87M
Analysts74.55
Price Target87.59 (-6.3%)
Short Float %4.9%
Short Ratio5.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.31%
Min EPS beat(2)4.72%
Max EPS beat(2)11.9%
EPS beat(4)2
Avg EPS beat(4)1.1%
Min EPS beat(4)-10.01%
Max EPS beat(4)11.9%
EPS beat(8)3
Avg EPS beat(8)-5.09%
EPS beat(12)5
Avg EPS beat(12)-7.34%
EPS beat(16)7
Avg EPS beat(16)-6.93%
Revenue beat(2)2
Avg Revenue beat(2)3.69%
Min Revenue beat(2)3.45%
Max Revenue beat(2)3.94%
Revenue beat(4)4
Avg Revenue beat(4)3%
Min Revenue beat(4)1.09%
Max Revenue beat(4)3.94%
Revenue beat(8)4
Avg Revenue beat(8)-0.25%
Revenue beat(12)6
Avg Revenue beat(12)-0.67%
Revenue beat(16)9
Avg Revenue beat(16)0.51%
PT rev (1m)1.57%
PT rev (3m)10.21%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)5.75%
EPS NY rev (1m)0.14%
EPS NY rev (3m)6.87%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)2.98%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)2.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.56 | ||
| Fwd PE | 12.64 | ||
| P/S | 3.98 | ||
| P/FCF | 19.05 | ||
| P/OCF | 18.2 | ||
| P/B | 4.38 | ||
| P/tB | 4.69 | ||
| EV/EBITDA | 13.6 |
EPS(TTM)6.42
EY6.87%
EPS(NY)7.39
Fwd EY7.91%
FCF(TTM)4.91
FCFY5.25%
OCF(TTM)5.14
OCFY5.49%
SpS23.48
BVpS21.36
TBVpS19.91
PEG (NY)0.04
PEG (5Y)N/A
Graham Number55.55
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.96% | ||
| ROE | 20.88% | ||
| ROCE | 21.89% | ||
| ROIC | 17.3% | ||
| ROICexc | 47.5% | ||
| ROICexgc | 57.26% | ||
| OM | 21.69% | ||
| PM (TTM) | 18.99% | ||
| GM | 93.41% | ||
| FCFM | 20.9% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
ROICexc(3y)25.32%
ROICexc(5y)N/A
ROICexgc(3y)31.6%
ROICexgc(5y)N/A
ROCE(3y)9.17%
ROCE(5y)N/A
ROICexgc growth 3Y-34.92%
ROICexgc growth 5Y-33.44%
ROICexc growth 3Y-36.33%
ROICexc growth 5Y-29.08%
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
F-Score6
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.04 | ||
| Debt/EBITDA | 0.03 | ||
| Cap/Depr | 49.5% | ||
| Cap/Sales | 0.98% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 92.43% | ||
| Profit Quality | 110.01% | ||
| Current Ratio | 2.85 | ||
| Quick Ratio | 2.78 | ||
| Altman-Z | 8.29 |
F-Score6
WACC8.74%
ROIC/WACC1.98
Cap/Depr(3y)83.51%
Cap/Depr(5y)185.09%
Cap/Sales(3y)1.73%
Cap/Sales(5y)3.66%
Profit Quality(3y)367.72%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
EPS Next Y378.66%
EPS Next 2Y136.69%
EPS Next 3Y88.47%
EPS Next 5Y27.17%
Revenue 1Y (TTM)14.76%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
Revenue Next Year15.16%
Revenue Next 2Y13.02%
Revenue Next 3Y11.75%
Revenue Next 5Y-0.47%
EBIT growth 1Y1425.09%
EBIT growth 3Y-44.05%
EBIT growth 5Y-23.34%
EBIT Next Year352.21%
EBIT Next 3Y84.5%
EBIT Next 5Y24.25%
FCF growth 1Y34.45%
FCF growth 3Y-24.05%
FCF growth 5Y-17.01%
OCF growth 1Y28.43%
OCF growth 3Y-23.52%
OCF growth 5Y-13.95%
INCYTE CORP / INCY FAQ
What is the fundamental rating for INCY stock?
ChartMill assigns a fundamental rating of 6 / 10 to INCY.
What is the valuation status for INCY stock?
ChartMill assigns a valuation rating of 8 / 10 to INCYTE CORP (INCY). This can be considered as Undervalued.
How profitable is INCYTE CORP (INCY) stock?
INCYTE CORP (INCY) has a profitability rating of 7 / 10.
What is the valuation of INCYTE CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for INCYTE CORP (INCY) is 14.56 and the Price/Book (PB) ratio is 4.38.
What is the earnings growth outlook for INCYTE CORP?
The Earnings per Share (EPS) of INCYTE CORP (INCY) is expected to grow by 378.66% in the next year.